C.A. Magaret
C.A. Magaret
Fred Hutchinson Cancer Research Center and Prevencio, Inc.
Adresse e-mail validée de fhcrc.org
Citée par
Citée par
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
M Rolland, PT Edlefsen, BB Larsen, S Tovanabutra, E Sanders-Buell, ...
Nature 490 (7420), 417-420, 2012
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial
M Rolland, S Tovanabutra, CC Allan, N Frahm, PB Gilbert, ...
Nature medicine 17 (3), 366-371, 2011
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120
N Karasavvas, E Billings, M Rao, C Williams, S Zolla-Pazner, RT Bailer, ...
AIDS research and human retroviruses 28 (11), 1444-1457, 2012
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections
S Gnanakaran, T Bhattacharya, M Daniels, BF Keele, PT Hraber, ...
PLoS pathogens 7 (9), e1002209, 2011
Basis and statistical design of the passive HIV-1 antibody mediated prevention (AMP) test-of-concept efficacy trials
PB Gilbert, M Juraska, AC deCamp, S Karuna, S Edupuganti, N Mgodi, ...
Statistical communications in infectious diseases 9 (1), 2017
Comparison of a high-resolution melting assay to next-generation sequencing for analysis of HIV diversity
MM Cousins, SS Ou, MJ Wawer, S Munshaw, D Swan, CA Magaret, ...
Journal of clinical microbiology 50 (9), 3054-3059, 2012
Machine learning competition in immunology–Prediction of HLA class I binding peptides
GL Zhang, HR Ansari, P Bradley, GC Cawley, T Hertz, X Hu, N Jojic, ...
Journal of immunological methods 374 (1-2), 1-4, 2011
Analysis of HLA A* 02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial
AJ Gartland, S Li, J McNevin, GD Tomaras, R Gottardo, H Janes, Y Fong, ...
Journal of virology 88 (15), 8242-8255, 2014
Higher T-cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial
HE Janes, KW Cohen, N Frahm, SC De Rosa, B Sanchez, J Hural, ...
The Journal of infectious diseases 215 (9), 1376-1385, 2017
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial
PT Edlefsen, M Rolland, T Hertz, S Tovanabutra, AJ Gartland, ...
PLoS computational biology 11 (2), e1003973, 2015
A Clinical and Biomarker Scoring System to Predict the Presence of Obstructive Coronary Artery Disease
AMBRRJK Nasrien E. Ibrahim, James L. Januzzi Jr., Craig A. Magaret, Hanna K ...
Journal of the American College of Cardiology 69 (9), 2017
Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials
M Juraska, CA Magaret, J Shao, LN Carpp, AJ Fiore-Gartland, ...
Proceedings of the National Academy of Sciences 115 (36), E8378-E8387, 2018
Analysis of HIV using a high resolution melting (HRM) diversity assay: automation of HRM data analysis enhances the utility of the assay for analysis of HIV incidence
MM Cousins, D Swan, CA Magaret, DR Hoover, SH Eshleman
PLoS One 7 (12), e51359, 2012
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
AC Decamp, M Rolland, PT Edlefsen, E Sanders-Buell, B Hall, ...
PloS one 12 (11), e0185959, 2017
A clinical, proteomics, and artificial intelligence‐driven model to predict acute kidney injury in patients undergoing coronary angiography
NE Ibrahim, CP McCarthy, S Shrestha, HK Gaggin, R Mukai, CA Magaret, ...
Clinical cardiology 42 (2), 292-298, 2019
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
CA Magaret, DC Benkeser, BD Williamson, BR Borate, LN Carpp, ...
PLoS computational biology 15 (4), e1006952, 2019
Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from the Catheter Sampled …
JLJ Cian P McCarthy, Roland R J van Kimmenade, Hanna K Gaggin, Mandy L Simon ...
Am J Cardiol 120 (1), 25-32, 2017
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature490: 417–420
M Rolland, PT Edlefsen, BB Larsen, S Tovanabutra, E Sanders-Buell, ...
A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial
T Hertz, MG Logan, M Rolland, CA Magaret, C Rademeyer, ...
Vaccine 34 (47), 5792-5801, 2016
OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial
M Rolland, S Tovanabutra, PB Gilbert, E Sanders-Buell, L Heath, ...
Retrovirology 6 (3), 1-1, 2009
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20